IRCT20200623047902N37
Recruiting
未知
Bioequivalence study of Dapagliflozin 10 mg manufactured by Actover Co. versus originator brand in healthy volunteers in fasting condition
Actover Co.0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Actover Co.
- Enrollment
- 24
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18\-28\)
- •Informed consent
- •Age (18\-55 years old)
Exclusion Criteria
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Dapagliflozin
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Bioequivalence study of dapagliflozin 10 mg tabletIRCT20230222057495N18Viana Darou Sanat Pharmaceutical company24
Recruiting
Not Applicable
Bioequivalence study of empagliflozin 10 mg tabletIn the present study, no disease was investigated..IRCT20230222057495N3Yab Daro Company24
Completed
Not Applicable
Comparative in vivo evaluation of 2 Empagliflozin 25 mg Combined Tablet formulations.IRCT20180620040164N57Darou darman Pars Co.24
Completed
Not Applicable
Bioequivalence Study of Dapagliflozin 10 mg Film-coated TabletsHealthyNCT06127212Dexa Medica Group24
Not yet recruiting
Not Applicable
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditionsIRCT20180620040164N13ACtover Pharmaceutical Co26